BACKGROUND: Accelerated atherosclerosis in patients with chronic kidney disease (CKD)
is still incompletely understood. Angiopoietin 1 (Ang-1) and Ang-2 are 55-kDa antagonistic …

Abstract Background. Angiopoietin-2 (Ang-2) is an antagonistic ligand of the endothelial-
specific Tie2 receptor. Patients on dialysis have markedly elevated Ang-2 levels, and those …

Background. The pathophysiology of aggravated atherosclerosis in chronic kidney disease
(CKD) is still incompletely understood. However, there is an increasing focus on non …

Volume status, congestion, endothelial activation, and injury all play roles in glomerular
filtration rate (GFR) decline. In this study, we aimed to determine whether the plasma …

Background The pathophysiological mechanisms of renal function progression in chronic
kidney disease (CKD) have still not been completely explored. In addition to well-known …

Background Chronic kidney disease (CKD) patients have higher prevalence of major
adverse cardiovascular events (MACE) and all-cause mortality. Endothelial damage and …

Angiopoietins (Angpt) and vascular endothelial growth factor (VEGF) have been associated
with cardiovascular disease. The study enrolled 270 pre-dialysis stage 3–5 CKD patients to …

Although cardiovascular disease (CVD) is the leading cause of mortality in patients with
chronic kidney disease (CKD), the pathophysiology is not thoroughly understood. Given that …

Background Endothelial activation has emerged as an early event in the pathogenesis of
cardiovascular disease. Angiopoietin-2 (Ang-2) has been identified as a nonredundant …

Cardiovascular disease (CVD) is increasingly recognised as a complication of childhood
chronic kidney disease (CKD) even in the absence of diabetes and hypertension. We …